Condition: BRCA1 Gene Mutation · BRCA2 Gene Mutation · RAD51C Gene Mutation · Sponsor: University Medical Center Nijmegen
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
This description comes directly from the study's public registry record.
Joanne A. de Hullu, MD, PhD · +31 (0) 24 36 16683 · Joanne.deHullu@radboudumc.nl
Karen H. Lu, MD, PhD · (713) 745-8902 · khlu@mdanderson.org
Always discuss trial participation with your own doctor first.
| UChicago Medicine | Chicago, Illinois, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Washington University Medical Center | St Louis, Missouri, United States | Recruiting |
| Mount Sinai Hospital | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Duke University Hospital | Durham, North Carolina, United States | Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Harris Health Lyndon B. Johnson Hospital | Houston, Texas, United States | Recruiting |
| MD Anderson Cancer Centre | Houston, Texas, United States | Recruiting |
| University of Washington | Seattle, Washington, United States | Recruiting |
| Chris O'Brien Lifehouse | Sydney, New South Wales, Australia | Recruiting |
+ 54 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04294927